Cat No.
CEI-0198
Description
Baricitinib (INCB28050, LY3009104) can inhibit JAK1 and JAK2 with IC50 of 5.9 nM and 5.7 nM.
Alias
INCB 28050
Synonyms
INCB 28050
CAS No.
1187594-09-7
Targets
JAK1, JAK2
Chemical Name
3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
M.Wt
371.41688
Purity
>99%
Solubility
DMSO 74 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
As an ATP competitive kinase inhibitor, INCB028050 (Baricitinib, LY3009104) was a potent inhibitor of JAK1 and JAK2 with IC50 values of 5.9 and 5.7 nM, respectively. INCB0-28050 (Baricitinib, LY3009104), a potent and selective inhibitor of JAK1/2, is shown to inhibit signaling from pathogenic cytokines such as IL-6 and IL-23. Inhibition of JAK signaling prevents the production of chemokines and cytokines associated with uncontrolled RA. In cell-based assays, INCB028050 proved to be a potent inhibitor of JAK signaling and function. In PBMCs, INCB028050 inhibited IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively. In isolated naive T-cells, INCB028050 also inhibited pSTAT3 stimulated by IL-23 (IC 50 = 20 nM).
